A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Pancrecarb Indications, Dosage, Storage, Stability - Pancrelipase
Pancrecarb Indications, Dosage, Storage, Stability - Pancrelipase
INDICATIONS
PANCRECARBâ (pancrelipase) delayed-release
capsules are indicated for patients with exocrine
pancreatic enzyme
insufficiency such as: cystic
fibrosis, chronic
pancreatitis, post-pancreatectomy,
post-gastrointestinal bypass surgery
(e.g. Billroth II gastroenterostomy), ductal obstruction from neoplasm
(e.g. of the pancreas
or common bile duct).
DOSAGE AND ADMINISTRATION
Dosage should be adjusted according to the severity of the exocrine
pancreatic insufficiency. Begin therapy
with one or two capsules with meals or snacks and adjust dosage
according to symptoms. Dose increases, if required, should be made
slowly, with careful monitoring of response
and symptomatology. It is important to ensure adequate hydration
of patients at all times while taking PANCRECARBâ
.
HOW SUPPLIED
PANCRECARBâ (pancrelipase) delayed-release
capsules are supplied as follows:
PANCRECARBâ MS-8 (clear, hard
gelatin capsule imprinted in blue
with "DCI" and "PANCRECARBâ
MS-8") in bottles of 100 (NDC 59767-0001-01).
STORAGE
Store at controlled room
temperature (15o-30oC,
59o-86oF) in a dry place. Do not refrigerate.
Keep bottle tightly closed. Dispense in a tight container.
Caution: Federal law
prohibits dispensing without prescription.
top
